This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Journals

New Recommendations and Guidelines from the SSC Subcommittee on Hemostasis & Malignancy

Tuesday, September 9, 2014   (0 Comments)
Share |

Evaluation of a New Commercial Assay to Measure Microparticle Tissue Factor Activity in Plasma: communication from the SSC of the ISTH

K. Tatsumi, S. Antoniak, D. M. Monroe III, A A. Khorana, N. Mackman and the Subcommittee on Hemostasis and Malignancy

Microparticles (MPs) are small membrane vesicles that are released by activated cells, such as monocytes, cells undergoing apoptosis and tumor cells [1]. Full-length tissue factor (flTF) is a transmembrane receptor for FVII/VIIa and is essentially undetectable in the blood of healthy individuals. However, intravascular levels of flTF are increased in a variety of diseases, including cancer and endotoxemia [1]. The majority of active flTF in plasma in these disease states is present on MPs.

Membership Management Software Powered by YourMembership  ::  Legal